Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in POEMS Syndrome
NCT04396496Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Sep 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in POEMS syndrome (POEMS), sponsored by University of Arkansas. Primary endpoint: Treatment Success at 360 days. Started Sep 2020; status: completed.
02
Drugs
daratumumab
03
Conditions
POEMS syndrome (POEMS)
Beyond the preview
Go deeper on NCT04396496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396496.